Small Molecule NVL2 Inhibitors, Dibenzothiazepinone and Dibenzazepinone Compounds for Cancer Treatment

The USPTO published a new patent application (US20260097047A1) filed December 4, 2025, disclosing small molecule inhibitors of the ribosome biogenesis factor NVL2. The compounds are based on dibenzothiazepinone and dibenzazepinone scaffolds and are directed toward treating cancers by inhibiting ribosome biogenesis, inducing p53, or directly inhibiting cancer cell proliferation. Methods for treating cancers and screening candidate therapeutics are also claimed.

Pharmaceutical companies and oncology researchers should monitor this application as it may impact future drug development programs targeting NVL2 and ribosome biogenesis pathways. Patent applications do not create immediate compliance obligations but represent potential future intellectual property that could require licensing or design-around strategies for competing therapeutic developers.